Key Insights

Highlights

Success Rate

80% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

7.1%

1 terminated out of 14 trials

Success Rate

80.0%

-6.5% vs benchmark

Late-Stage Pipeline

21%

3 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed with results

Key Signals

1 with results80% success

Data Visualizations

Phase Distribution

11Total
Not Applicable (5)
P 1 (1)
P 2 (2)
P 3 (2)
P 4 (1)

Trial Status

Completed4
Recruiting3
Unknown2
Not Yet Recruiting2
Terminated1
Active Not Recruiting1

Trial Success Rate

80.0%

Benchmark: 86.5%

Based on 4 completed trials

Clinical Trials (14)

Showing 14 of 14 trials
NCT07567378Not Yet Recruiting

CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry

NCT07415720Not ApplicableRecruiting

Artichoke By-products Rich in Hydroxycinnamic Acids and Mediterranean Diet for Type 2 Diabetes Prevention.

NCT07373795Not ApplicableCompleted

Gummy Candies With Maqui Berry

NCT07336563Not Yet Recruiting

ENDOCARE-SCREEN: Metabolic Liver Dysfunction Screening Study

NCT04128969Phase 2Active Not Recruiting

Causal Mechanisms in Adolescent Arterial Stiffness

NCT07221279Not ApplicableRecruiting

Prescription of Step Counts for Targeted Changes in Body Composition and Cardiometabolic Risk in Overweight/Obese Adults

NCT07094776Enrolling By Invitation

Evaluation of MG53 (TRIM72) Levels in Women With Polycystic Ovary Syndrome: An Observational Study

NCT06806345Phase 1RecruitingPrimary

Hyperbaric Oxygen Therapy on Insulin Resistance in Postmenopause

NCT04028895Not ApplicableTerminatedPrimary

Diagnostic Interest of the IRAP Protein (Insulin Regulated Amino Peptidase) in Insulin Resistance

NCT03011775Phase 4Completed

Effect of Pioglitazone on Insulin Resistance, Atherosclerosis Progression and Clinical Course of Coronary Heart Disease

NCT04221152Phase 3Unknown

A Extension Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance ( EMPIRE-02 )

NCT04018365Phase 3Unknown

A Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance

NCT03716336Not ApplicableCompletedPrimary

Aerobic and Strength Training With Caloric Restriction on Insulin Resistance in Obese Premenopausal Women

NCT03741686Phase 2CompletedPrimary

Effect of Konjac-mannan in Individuals With Insulin-Resistance Syndrome

Showing all 14 trials

Research Network

Activity Timeline